var data={"title":"Bortezomib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bortezomib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5754?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bortezomib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bortezomib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142137\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Velcade</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855139\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Velcade</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142156\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Proteasome Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142140\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consecutive doses should be separated by at least 72 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma (first-line therapy; in combination with melphalan and prednisone):</b> IV, SubQ: 1.3 mg/m<sup>2</sup> days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day treatment cycle for 4 cycles, followed by 1.3 mg/m<sup>2</sup> days 1, 8, 22, and 29 of a 42-day treatment cycle for 5 cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Retreatment may be considered for multiple myeloma patients who had previously responded to bortezomib (either as monotherapy or in combination) and who have relapsed at least 6 months after completing prior bortezomib therapy; initiate at the last tolerated dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative first-line therapy (off-label dosing/combinations):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CyBorD regimen: IV: 1.5 mg/m<sup>2</sup> days 1, 8, 15, and 22 of a 28-day treatment cycle for 4 cycles (may continue beyond 4 cycles) in combination with cyclophosphamide and dexamethasone (Khan 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PAD regimen: IV: Induction: 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 28-day treatment cycle for 3 cycles (in combination with doxorubicin and dexamethasone), followed by conditioning/stem cell transplantation, and then maintenance bortezomib 1.3 mg/m<sup>2</sup> once every 2 weeks for 2 years (Sonneveld 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VD regimen: IV: Induction: 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with dexamethasone) for 4 cycles, followed by autologous stem cell transplantation (Harousseau 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VRd regimen: IV: 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 21-day treatment cycle for 8 cycles (in combination with lenalidomide and dexamethasone) (Durie 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VTd regimen: IV: 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 21-day treatment cycle for 3 induction cycles (in combination with thalidomide and dexamethasone), followed by tandem transplant, then (3 months after second transplant) 1.3 mg/m<sup>2</sup> days 1, 8, 15, and 22 every 35 days for 2 consolidation cycles (in combination with thalidomide and dexamethasone) (Cavo 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &ge;65 years of age: IV: 1.3 mg/m<sup>2</sup> days 1, 8, 15, and 22 of a 35-day treatment cycle, in combination with <b>either</b> melphalan and prednisone or melphalan, prednisone, and thalidomide (Boccadoro 2010; Bringhen 2010; Palumbo 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma (relapsed):</b> IV, SubQ: 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle. Therapy extending beyond 8 cycles may be administered by the standard schedule or may be given once weekly for 4 weeks (days 1, 8, 15, and 22), followed by a 13-day rest (days 23 through 35).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Retreatment may be considered for multiple myeloma patients who had previously responded to bortezomib (either as monotherapy or in combination) and who have relapsed at least 6 months after completing prior bortezomib therapy; initiate at the last tolerated dose. Administer twice weekly for 2 weeks on days 1, 4, 8, and 11 of a 21-day treatment cycle (either as a single-agent or in combination with dexamethasone) for a maximum of 8 cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative relapsed therapy (off-label dosing):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 21-day treatment cycle for at least 8 cycles or until disease progression or unacceptable toxicity (in combination with liposomal doxorubicin) (Orlowski 2007) <b>or </b>1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 21-day treatment cycle for 8 cycles followed by (if deriving benefit) 1.3 mg/m<sup>2</sup> days 1, 8, 22, and 29 of a 42-day treatment cycle for 4 cycles (in combination with panobinostat and dexamethasone) (San-Miguel 2014) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ: 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 every 21 days (in combination with daratumumab and dexamethasone) for 8 cycles (Palumbo 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mantle cell lymphoma (first-line therapy; in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [VcR-CAP]): IV:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, 11 of a 21-day treatment cycle for 6 cycles. If response first documented at cycle 6, treatment for an additional 2 cycles is recommended (Roback 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mantle cell lymphoma (relapsed): IV, SubQ:</b> 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 17 cycles (Fisher 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antibody-mediated rejection in cardiac transplantation, treatment (off-label use):</b> IV: 1.3 to 1.5 mg/m<sup>2</sup> typically given on days 1, 4, 8, and 11 (treatment frequency varies) for a total of 4 doses (treatment duration may vary) (AHA [Colvin 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cutaneous or peripheral T-cell lymphoma, relapsed/refractory (off-label use):</b> IV: 1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of a 21-day treatment cycle for up to 6 cycles (Zinzani 2007). Additional data may be necessary to further define the role of bortezomib in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Follicular lymphoma, relapsed/refractory (off-label use):</b> IV: 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 28-day treatment cycle, in combination with bendamustine and rituximab for 6 cycles (Friedberg 2011) <b>or</b> 1.6 mg/m<sup>2</sup> days 1, 8, 15, and 22 of a 35-day treatment cycle, in combination with bendamustine and rituximab for 5 cycles (Fowler 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic light-chain amyloidosis (off-label use):</b> IV: 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 21-day treatment cycle (with or without dexamethasone) (Kastritis 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Waldenstr&ouml;m's macroglobulinemia, relapsed/refractory (off-label use):</b> IV: 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 21-day treatment cycle; continue until disease progression or until 2 cycles after achieving a complete response (Chen 2007) or 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 21-day treatment cycle (in combination with dexamethasone and rituximab) (Treon 2009) <b>or</b> 1.6 mg/m<sup>2</sup> days 1, 8, and 15 of a 28-day treatment cycle for 6 cycles (in combination with rituximab) (Ghobrial 2010). The Eighth International Workshop on Waldenstr&ouml;m Macroglobulinemia (IWWM) recommends administering bortezomib subcutaneously (if possible) and as a once weekly regimen; if urgent IgM level reduction is necessary, may initiate with a twice weekly regimen for 1 to 2 cycles followed by once weekly dosing (Leblond 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2655956\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142141\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment is necessary. The International Myeloma Working Group (IMWG) recommendations suggest that bortezomib may be safely administered to patients with renal impairment, including those on dialysis (Dimopoulos 2016). The IMWG recommends the use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Disease (MDRD) formula to evaluate renal function estimation in multiple myeloma patients with a stable serum creatinine. Dialysis may reduce bortezomib concentrations; administer postdialysis (Leal 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142142\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (bilirubin &le;1 times ULN and AST &gt;ULN or bilirubin &gt;1 to 1.5 times ULN): No initial dose adjustment is necessary (LoRusso, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate (bilirubin &gt;1.5 to 3 times ULN) and severe impairment (bilirubin &gt;3 times ULN): Reduce initial dose to 0.7 mg/m<sup>2</sup> in the first cycle; based on patient tolerance, may consider dose escalation to 1 mg/m<sup>2</sup> (LoRusso 2012) or further dose reduction to 0.5 mg/m<sup>2</sup> in subsequent cycles</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20339769\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:</i> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142157\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myeloma (first-line therapy):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets should be &ge;70,000/mm<sup>3</sup>, ANC should be &ge;1000/mm<sup>3</sup>, and nonhematologic toxicities should resolve to grade 1 or baseline prior to therapy initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets &le;30,000/mm<sup>3</sup> or ANC &le;750/mm<sup>3</sup> on bortezomib day(s) (except day 1): Withhold bortezomib; if several bortezomib doses in consecutive cycles are withheld, reduce dose 1 level (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade &ge;3 nonhematological toxicity (other than neuropathy): Withhold bortezomib until toxicity resolves to grade 1 or baseline. May reinitiate bortezomib at 1 dose level reduction (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuropathic pain and/or peripheral sensory or motor neuropathy: See &quot;Neuropathic pain and/or peripheral sensory, motor, or autonomic neuropathy&quot; toxicity adjustment guidelines below.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mantle cell lymphoma (first-line therapy):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets should be &ge;100,000/mm<sup>3</sup>, ANC should be &ge;1,500/mm<sup>3</sup>, hemoglobin should be &ge;8 g/dL, and nonhematologic toxicities should resolve to grade 1 or baseline prior to each cycle (cycle 2 and beyond).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets &lt;25,000/mm<sup>3</sup> or &ge; grade 3 neutropenia on bortezomib day(s) (except day 1): Withhold bortezomib for up to 2 weeks until platelets are &ge;25,000/mm<sup>3</sup> and/or ANC &ge;750/mm<sup>3</sup>, then reduce dose 1 level (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose). If hematologic toxicity does not resolve after withholding therapy, discontinue bortezomib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade &ge;3 nonhematological toxicity (other than neuropathy): Withhold bortezomib until toxicity resolves to &le; grade 2. May reinitiate bortezomib at 1 dose level reduction (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuropathic pain and/or peripheral sensory or motor neuropathy: See &quot;Neuropathic pain and/or peripheral sensory or motor neuropathy&quot; toxicity adjustment guidelines below.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Relapsed multiple myeloma and mantle cell lymphoma: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 nonhematological (excluding neuropathy) or grade 4 hematological toxicity: Withhold until toxicity resolved; may reinitiate with a 25% dose reduction (1.3 mg/m<sup>2</sup>/dose reduced to 1 mg/m<sup>2</sup>/dose; 1 mg/m<sup>2</sup>/dose reduced to 0.7 mg/m<sup>2</sup>/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain and/or peripheral sensory, motor, or autonomic neuropathy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Consider subQ administration in patients with preexisting or at high risk for peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 1 (asymptomatic; deep tendon reflex loss or paresthesia) without pain or loss of function: No action needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 1 with pain or grade 2 (moderate symptoms; limiting instrumental activities of daily living): Reduce dose to 1 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 2 with pain or grade 3 (severe symptoms; limiting self-care activities of daily living): Withhold until toxicity resolved, may reinitiate at 0.7 mg/m<sup>2</sup> once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 (life-threatening consequences with urgent intervention indicated) and/or severe autonomic neuropathy: Discontinue therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142118\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Velcade: 3.5 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3.5 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142106\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142120\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> The reconstituted concentrations for IV and SubQ administration are different; use caution when calculating the volume for each route and dose. Consider SubQ administration in patients with preexisting or at high risk for peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IV: Administer via rapid IV push (3 to 5 seconds). When administering in combination with rituximab for first-line therapy of mantle cell lymphoma, administer bortezomib prior to rituximab.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ (Velcade only): Subcutaneous administration of bortezomib 1.3 mg/m<sup>2</sup> days 1, 4, 8, and 11 of a 21-day treatment cycle has been studied in a limited number of patients with relapsed multiple myeloma; doses were administered subcutaneously (concentration of 2.5 mg/mL) into the thigh or abdomen, rotating the injection site with each dose; injections at the same site within a single cycle were avoided (Moreau 2010; Moreau 2011). Response rates were similar to IV administration; decreased incidence of grade 3 or higher adverse events were observed with SubQ administration. Administer at least 1 inch from an old site and never administer to tender, bruised, erythematous, or indurated sites. If injection site reaction occurs, the more dilute 1 mg/mL concentration may be used SubQ (or IV administration of 1 mg/mL concentration may be considered).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>For SubQ (Velcade) or IV administration only; fatalities have been reported with inadvertent intrathecal administration.</b> Bortezomib should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> The generic product (Fresenius Kabi) is NOT approved for subcutaneous administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130903\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142119\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mantle cell lymphoma:</b> Treatment of mantle cell lymphoma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma:</b> Treatment of multiple myeloma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475219\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Antibody-mediated rejection (AMR) in cardiac transplantation (treatment); Cutaneous T-cell lymphomas (mycosis fungoides), relapsed/refractory; Follicular lymphoma, relapsed/refractory; Peripheral T-cell lymphoma, relapsed/refractory; Systemic light-chain amyloidosis; Waldenstr&ouml;m macroglobulinemia, relapsed/refractory</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401586\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bortezomib may be confused with carfilzomib, ixazomib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The reconstituted concentrations for IV and SubQ administration are different; use caution when calculating the volume for each route and dose. The manufacturer provides stickers to facilitate identification of the route for reconstituted vials.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">For SubQ (Velcade only) or IV administration only. Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Bortezomib should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep bortezomib in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Bortezomib should <b>NOT</b> be delivered to the patient at the same time with any medications intended for intrathecal administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142110\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidences reported are associated with monotherapy. Additional adverse reactions reported with mono- or combination therapy; frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension (8% to 9%), cardiac disease (treatment emergent; 8%), acute pulmonary edema (&le;1%), cardiac failure (&le;1%), cardiogenic shock (&le;1%), pulmonary edema (&le;1%), aggravated atrial fibrillation, angina pectoris, atrial flutter, atrioventricular block, bradycardia, cerebrovascular accident, deep vein thrombosis, edema, embolism (peripheral), facial edema, hemorrhagic stroke, hypertension, ischemic heart disease, myocardial infarction, pericardial effusion, pericarditis, peripheral edema, phlebitis, portal vein thrombosis, pulmonary embolism, septic shock, sinoatrial arrest, subdural hematoma, torsades de pointes, transient ischemic attacks, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Peripheral neuropathy (IV: 35% to 54%; SubQ: 37%; grade &ge;2: 24% to 39%; grade &ge;3: SubQ: 5% to 6%; IV: 7% to 15%; grade 4: &lt;1%), fatigue (7% to 52%), neuralgia (23%), headache (10% to 19%), paresthesia (7% to 19%), dizziness (10% to 18%; excludes vertigo), agitation, anxiety, ataxia, brain disease, cerebral hemorrhage, chills, coma, confusion, cranial nerve palsy, dysarthria, dysautonomia, dysesthesia, insomnia, malaise, mental status changes, motor dysfunction, paralysis, psychosis, seizure, spinal cord compression, suicidal ideation, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (12% to 23%), pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration (2%), amyloid heart disease, hyperglycemia (diabetic patients), hyperkalemia, hypernatremia, hyperuricemia, hypocalcemia, hypoglycemia (diabetic patients), hypokalemia, hyponatremia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (19% to 52%), nausea (14% to 52%), constipation (24% to 34%), vomiting (9% to 29%), anorexia (14% to 21%), abdominal pain (11%), decreased appetite (11%), cholestasis, duodenitis (hemorrhagic), dysphagia, fecal impaction, gastritis (hemorrhagic), gastroenteritis, gastroesophageal reflux disease, hematemesis, intestinal obstruction, intestinal perforation, melena, oral candidiasis, pancreatitis, paralytic ileus, peritonitis, stomatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Bladder spasm, hematuria, hemorrhagic cystitis, urinary incontinence, urinary retention, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Thrombocytopenia (16% to 52%; grade 3: 5% to 24%; grade 4: 3% to 7%; nadir: Day 11; recovery: By day 21), neutropenia (5% to 27%; grade 3: 8% to 18%; grade 4: 2% to 4%; nadir: Day 11; recovery: By day 21), anemia (12% to 23%; grade 3: 4% to 6%; grade 4: &lt;1%). leukopenia (18% to 20%; grade 3: 5%; grade 4: &le;1%), hemorrhage (&ge;grade 3: 2%), disseminated intravascular coagulation, febrile neutropenia, lymphocytopenia, oral mucosal petechiae</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Ascites, hepatic failure, hepatic hemorrhage, hepatitis, hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction, hypersensitivity angiitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Herpes zoster (reactivation; 6% to 11%), herpes simplex infection (1% to 3%), herpes zoster (1% to 2%), aspergillosis, bacteremia, listeriosis, toxoplasmosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (mostly redness; SubQ: 6%), irritation at injection site (IV 5%), catheter infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness (7% to 16%), arthralgia, back pain, bone fracture, limb pain, myalgia, ostealgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, conjunctival infection, conjunctival irritation, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Bilateral hydronephrosis, nephrolithiasis, proliferative glomerulonephritis, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea (11%), pneumonia (1% to 3%), adult respiratory distress syndrome, aspiration pneumonia, atelectasis, bronchitis, chronic obstructive pulmonary disease (exacerbation), cough, epistaxis, hemoptysis, hypoxia, laryngeal edema, nasopharyngitis, pleural effusion, pneumonitis, pulmonary hypertension, pulmonary infiltrates (including diffuse), respiratory tract infection, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (8% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute ischemic stroke, amyloidosis, autonomic neuropathy, blindness, cardiac tamponade, chalazion (Fraunfelder 2016), deafness (bilateral), decreased left ventricular ejection fraction, dysgeusia, dyspepsia, hemolytic-uremic syndrome, herpes meningoencephalitis, increased gamma-glutamyl transferase, increased serum alkaline phosphatase, increased serum transaminases, interstitial pneumonitis, intestinal obstruction, ischemic colitis, ocular herpes simplex, optic neuritis, optic neuropathy, progressive multifocal leukoencephalopathy, prolonged Q-T interval on ECG, pulmonary disease, respiratory insufficiency, reversible posterior leukoencephalopathy syndrome, sepsis, SIADH, Stevens-Johnson syndrome, subarachnoid hemorrhage, Sweet syndrome, syncope, tachycardia, toxic epidermal necrolysis, tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142123\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (excluding local reactions) to bortezomib, boron, boric acid (generic product), glycine (generic product), mannitol (Velcade), or any component of the formulation; administration via the intrathecal route</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142108\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Hematologic toxicity, including grade 3 and 4 neutropenia and thrombocytopenia may occur; risk is increased in patients with pretreatment platelet counts &lt;75,000/mm<sup>3</sup>. Monitor frequently throughout treatment; may require treatment interruption, or dosage reduction. Management with platelet transfusions, supportive care, and/or myeloid growth factors may be necessary. Nadirs generally occur following the last dose of a cycle and recover prior to the next cycle. Hemorrhage (gastrointestinal and intracerebral) due to low platelet count has been observed. Neutropenic fever has been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Acute development or exacerbation of HF and new onset decreased left ventricular ejection fraction (LVEF) have been reported with bortezomib; some cases have occurred in patients without risk factors for HF and/or decreased LVEF. Monitor closely in patients with risk factors for HF or existing heart disease. Isolated case of QTc prolongation have been reported with bortezomib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Nausea, vomiting, diarrhea, or constipation may occur; may require antiemetics or antidiarrheals. Ileus may occur. Administer fluid and electrolytes to prevent dehydration; interrupt therapy for severe symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Acute liver failure has been reported (rarely) in patients receiving multiple concomitant medications and with serious underlying conditions. Hepatitis, transaminase increases, and hyperbilirubinemia have also been reported; interrupt therapy to assess reversibility. Use caution in patients with hepatic dysfunction; reduced initial doses are recommended for moderate and severe hepatic impairment (exposure is increased); closely monitor for toxicities. Limited data exists for patients that have been rechallenged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Herpes reactivation: Herpes (zoster and simplex) reactivation has been reported with bortezomib; consider antiviral prophylaxis during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity, angioedema, and laryngeal edema have been reported with bortezomib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Bortezomib may cause hypotension (including postural and orthostatic); use caution with dehydration, history of syncope, or medications associated with hypotension (may require adjustment of antihypertensive medication, hydration, and mineralocorticoids and/or sympathomimetics).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Bortezomib may cause or worsen peripheral neuropathy (usually sensory but may be mixed sensorimotor); risk may be increased with previous use of neurotoxic agents or preexisting peripheral neuropathy (in patients with preexisting neuropathy, use only after risk versus benefit assessment); monitor for signs and symptoms; adjustment of dose and/or schedule may be required. The incidence of grades 2 and 3 peripheral neuropathy may be lower with SubQ route (compared to IV); consider SubQ administration in patients with preexisting or at high risk for peripheral neuropathy. The majority of patients with &ge; grade 2 peripheral neuropathy have improvement in or resolution of symptoms with dose adjustments or discontinuation. In a study of elderly patients receiving a weekly bortezomib schedule with combination chemotherapy, the incidence of peripheral neuropathy was significantly reduced without an effect on outcome (Boccadoro 2010; Palumbo 2009). The generic product (by Fresenius Kabi) is NOT approved for subcutaneous administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Posterior reversible leukoencephalopathy syndrome: Posterior reversible leukoencephalopathy syndrome (PRES, formerly RPLS) has been reported (rarely). Symptoms of PRES include confusion, headache, hypertension, lethargy, seizure, blindness and/or other vision, or neurologic disturbances; discontinue bortezomib if PRES occurs. MRI is recommended to confirm PRES diagnosis. The safety of reinitiating bortezomib in patients previously experiencing PRES is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) has been rarely observed; evaluate promptly any new onset or worsening neurologic symptoms (eg, confusion, loss of balance, vision disturbances, reduced strength or weakness in an arm/leg).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Pulmonary disorders (some fatal) including pneumonitis, interstitial pneumonia, lung infiltrates, and acute respiratory distress syndrome (ARDS) have been reported. Pulmonary hypertension (without left heart failure or significant pulmonary disease) has been reported rarely. Promptly evaluate with new or worsening cardiopulmonary symptoms; therapy interruption may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome has been reported with bortezomib; risk is increased in patients with high tumor burden prior to treatment; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Hyper- and hypoglycemia may occur in diabetic patients receiving oral hypoglycemics; monitor; may require adjustment of diabetes medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Coadministration of strong CYP3A4 inhibitors may increase bortezomib exposure; monitor for toxicity and consider dose reduction if concurrent therapy cannot be avoided. Efficacy may be reduced when administered with strong CYP3A4 inducers; concomitant use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate administration: <b>For SubQ (Velcade only) or IV administration only</b><b>.</b> Intrathecal administration is contraindicated; inadvertent intrathecal administration has resulted in death. Bortezomib should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep bortezomib in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Bortezomib should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration. The reconstituted concentrations for IV and SubQ administration are different; use caution when calculating the volume for each route and dose. The manufacturer provides stickers to facilitate identification of the route for reconstituted vials. The generic product (by Fresenius Kabi) is approved for IV administration only.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142150\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (major), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142112\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8509&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May diminish the therapeutic effect of Bortezomib. Management: Patients should avoid taking vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy.  It is probably unnecessary to advise patients to avoid foods/beverages that contain vitamin C (e.g., citrus fruits, etc.).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Bortezomib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bortezomib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Green Tea: May diminish the antineoplastic effect of Bortezomib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May diminish the therapeutic effect of Bortezomib. Specifically, the vitamin C (ascorbic acid) found in many multivitamins may impair the clinical effects of bortezomib. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy.  It is likely unnecessary, though, to advise patients to avoid dietary sources of vitamin C.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Bortezomib. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins with bortezomib.  It is probably unnecessary to restrict or limit vitamin C-containing foods/beverages.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May diminish the therapeutic effect of Bortezomib. Specifically, vitamin C may decrease bortezomib therapeutic effects. Management: Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy.  It is likely unnecessary, though, to advise patients to avoid dietary sources of vitamin C.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Bortezomib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142126\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on the mechanism of action and on findings in animal reproduction studies, bortezomib may cause fetal harm if administered during pregnancy. Verify pregnancy status in women of reproductive potential prior to initiating therapy; women of reproductive potential should avoid becoming pregnant during bortezomib treatment. Females and males of reproductive potential should use effective contraception during and for at least 2 months following bortezomib treatment (refer to specific product labeling for details). Bortezomib may potentially affect male or female fertility (based on the mechanism of action).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142127\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if bortezomib is present in breast milk. The manufacturer recommends lactating women avoid breastfeeding during and for 2 months following bortezomib treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6894443\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Green tea and green tea extracts may diminish the therapeutic effect of bortezomib and should be avoided (Golden 2009). Avoid grapefruit juice. Avoid additional, nondietary sources of ascorbic acid supplements, including multivitamins containing ascorbic acid (may diminish bortezomib activity) during treatment, especially 12 hours before and after bortezomib treatment (Perrone 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142116\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (monitor frequently throughout therapy); liver function tests (in patients with existing hepatic impairment); verify pregnancy status in women of reproductive potential prior to therapy initiation; signs/symptoms of peripheral neuropathy, dehydration, hypotension, PRES, or PML; renal function, baseline chest x-ray and then periodic pulmonary function testing (with new or worsening pulmonary symptoms)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142107\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bortezomib inhibits proteasomes, enzyme complexes which regulate protein homeostasis within the cell. Specifically, it reversibly inhibits chymotrypsin-like activity at the 26S proteasome, leading to activation of signaling cascades, cell-cycle arrest, and apoptosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142122\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~498 to 1,884 L/m<sup>2</sup>; distributes widely to peripheral tissues</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~83%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic primarily via CYP2C19 and 3A4 and to a lesser extent CYP1A2; forms metabolites (inactive) via deboronization followed by hydroxylation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Single dose: IV: 9 to 15 hours; Multiple dosing: 1 mg/m<sup>2</sup>: 40 to 193 hours; 1.3 mg/m<sup>2</sup>: 76 to 108 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323023\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Bortezomib Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.5 mg (1): $1,923.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Velcade Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.5 mg (1): $1,923.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F142128\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bomib (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Bortega (CZ);</li>\n      <li>Egybort (LK);</li>\n      <li>Exfucikanet (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Mibor (LK);</li>\n      <li>Neomib (PH);</li>\n      <li>Nyubortez (UA);</li>\n      <li>Velcade (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JM, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PA, PE, PH, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SR, TH, TR, TT, TW, VE, VN);</li>\n      <li>Velkeyd (UA);</li>\n      <li>Zegomib (CZ);</li>\n      <li>Zuricade (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Agathocleous A, Rohatiner A, Rule S, et al, &ldquo;Weekly Versus Twice Weekly Bortezomib Given in Conjunction With Rituximab, in Patients With Recurrent follicular Lymphoma, Mantle Cell Lymphoma and Waldenstr&ouml;m Macroglobulinaemia,&rdquo; <i>Br J Haematol</i>, 2010, 151(4):346-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20880120/pubmed\" target=\"_blank\" id=\"20880120\">20880120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andre P, Cisternino S, Chiadmi F, et al, &ldquo;Stability of Bortezomib 1-mg/mL Solution in Plastic Syringe and Glass Vial,&rdquo; <i>Ann Pharmacother</i>, 2005, 39(9):1462-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15985470/pubmed\" target=\"_blank\" id=\"15985470\">15985470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arnulf B, Pylypenko H, Grosicki S, et al, &ldquo;Updated survival Analysis of a Randomized, Phase 3 Study of Subcutaneous versus Intravenous Bortezomib in Patients With Relapsed Multiple Myeloma,&rdquo; <i>Haematologica</i>, 2012, 97(12):1925-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22689676/pubmed\" target=\"_blank\" id=\"22689676\">22689676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boccadoro M, Bringhen S, Gaidano G, et al, &ldquo;Bortezomib, Melphalan, Prednisone, and Thalidomide (VMPT) Followed by Maintenance With Bortezomib and Thalidomide (VT) for Initial Treatment of Elderly Multiple Myeloma Patients,&rdquo; <i>J Clin Oncol</i>, 2010, 28(7s):8013 [abstract 8013 from 2010 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bortezomib [prescribing information]. Lake Zurich, IL: Fresenius Kabi; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bringhen S, Larocca A, Rossi D, et al, &ldquo;Efficacy and Safety of Once-Weekly Bortezomib in Multiple Myeloma Patients,&rdquo; <i>Blood</i>, 2010, 116(23):4745-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/ 20807892/pubmed\" target=\"_blank\" id=\" 20807892\"> 20807892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cavalli F, Rooney B, Pei L, et al. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT). <i>J Clin Oncol</i>. 2014;32(5s):8500. [Abstract 8500 from 2014 ASCO annual meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cavo M, Pantani L, Petrucci MT, et al, &ldquo;Bortezomib-Thalidomide-Dexamethasone Is Superior to Thalidomide-Dexamethasone as Consolidation Therapy After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma,&rdquo; <i>Blood</i>, 2012, 120(1):9-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22498745/pubmed\" target=\"_blank\" id=\"22498745\">22498745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cavo M, Tacchetti P, Patriarca F, et al, &ldquo;Bortezomib With Thalidomide Plus Dexamethasone Compared With Thalidomide Plus Dexamethasone as Induction Therapy Before, and Consolidation Therapy After, Double Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Randomised Phase 3 Study,&rdquo; <i>Lancet</i>, 2010, 376(9758):2075-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21146205/pubmed\" target=\"_blank\" id=\"21146205\">21146205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chanan-Khan AA, Kaufman JL, Mehta J, et al, &ldquo;Activity and Safety of Bortezomib in Multiple Myeloma Patients With Advanced Renal Failure: A Multicenter Retrospective Study,&rdquo; <i>Blood</i>, 2006, 109(9):2604-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17138816/pubmed\" target=\"_blank\" id=\"17138816\">17138816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chanan-Khan A, Sonneveld P, Schuster MW, et al, &quot;Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study,&quot; <i>J Clin Oncol</i>, 2008, 26(29):4784-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/18711175/pubmed\" target=\"_blank\" id=\"18711175\">18711175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17353550\"></a>Chen CI, Kouroukis CT, White D, et al, &ldquo;Bortezomib is Active in Patients With Untreated or Relapsed Waldenstrom's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group,&rdquo; <i>J Clin Oncol</i>, 2007, 25(12):1570-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17353550/pubmed\" target=\"_blank\" id=\"17353550\">17353550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colvin MM, Cook JL, Chang P, et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;131(18):1608-1639.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25838326/pubmed\" target=\"_blank\" id=\"25838326\">25838326</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Mateos MV, Richardson PG, et al, &ldquo;Risk Factors for, and Reversibility of, Peripheral Neuropathy Associated With Bortezomib-Melphalan-Prednisone in Newly Diagnosed Patients With Multiple Myeloma: Subanalysis of the Phase 3 VISTA Study,&rdquo; <i>Eur J Haematol</i>, 2011, 86(1):23-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21146205/pubmed\" target=\"_blank\" id=\"21146205\">21146205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Garc&iacute;a-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i>. 2013;122(19):3276-3782. doi: 10.1182/blood-2013-05-503862.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/24004667/pubmed\" target=\"_blank\" id=\"24004667\">24004667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Richardson PG, Schlag R, et al, &ldquo;VMP (Bortezomib, Melphalan, and Prednisone) is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study,&rdquo; <i>J Clin Oncol</i>, 2009, 27(36):6086-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19858394/pubmed\" target=\"_blank\" id=\"19858394\">19858394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016;34(13):1544-1557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/26976420/pubmed\" target=\"_blank\" id=\"26976420\">26976420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2017;389(10068):519-527.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/28017406/pubmed\" target=\"_blank\" id=\"28017406\">28017406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engelhardt M, Udi J, Kleber M, et al, &ldquo;European Myeloma Network: The 3rd Trialist Forum Consensus Statement from the European Experts Meeting on Multiple Myeloma,&rdquo; <i>Leuk Lymphoma</i>, 2010, 51(11):2006-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20807087/pubmed\" target=\"_blank\" id=\"20807087\">20807087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher RI, Bernstein SH, Kahl BS, et al, &ldquo;Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2006, 24(30):4867-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17001068/pubmed\" target=\"_blank\" id=\"17001068\">17001068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21810687\"></a>Fowler N, Kahl BS, Lee P, et al, &ldquo;Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study,&rdquo; <i>J Clin Oncol</i>, 2011, 29(25):3389-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21810687/pubmed\" target=\"_blank\" id=\"21810687\">21810687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraunfelder FW, Yang HK. Association between bortezomib therapy and eyelid chalazia. <i>JAMA Ophthalmol</i>. 2016;134(1):88-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/26469392/pubmed\" target=\"_blank\" id=\"26469392\">26469392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21239695\"></a>Friedberg JW, Vose JM, Kelly JL, et al, &ldquo;The Combination of Bendamustine, Bortezomib, and Rituximab for Patients With Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma,&rdquo; <i>Blood</i>, 2011, 117(10):2807-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21239695/pubmed\" target=\"_blank\" id=\"21239695\">21239695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraunfelder FW, Yang HK. Association between bortezomib therapy and eyelid chalazia. <i>JAMA Ophthalmol</i>. 2016;134(1):88-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/26469392 /pubmed\" target=\"_blank\" id=\"26469392 \">26469392 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20142586\"></a>Ghobrial IM, Hong F, Padmanabhan S, et al, &ldquo;Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia,&rdquo; <i>J Clin Oncol</i>, 2010, 28(8):1422-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20142586/pubmed\" target=\"_blank\" id=\"20142586\">20142586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilbar PJ and Seger AC, &ldquo;Fatalities Resulting From Accidental Intrathecal Administration of Bortezomib: Strategies for Prevention,&rdquo; <i>J Clin Oncol</i>, 2012, 30(27):3427-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22851559/pubmed\" target=\"_blank\" id=\"22851559\">22851559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golden EB, Lam PY, Kardosh A, et al, &ldquo;Green Tea Polyphenols Block the Anticancer Effects of Bortezomib and Other Boronic Acid-Based Proteasome Inhibitors,&rdquo; <i>Blood</i>, 2009, 113(23):5927-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19190249/pubmed\" target=\"_blank\" id=\"19190249\">19190249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harousseau JL, Attal M, Avet-Loiseau H, et al, &ldquo;Bortezomib Plus Dexamethasone is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone as Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial,&rdquo; <i>J Clin Oncol</i>, 2010, 28(30):4621-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20823406/pubmed\" target=\"_blank\" id=\"20823406\">20823406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iwamoto T, Ishibashi M, Fujieda A, et al, &ldquo;Drug Interaction Between Itraconazole and Bortezomib: Exacerbation of Peripheral Neuropathy and Thrombocytopenia Induced by Bortezomib,&rdquo; <i>Pharmacotherapy</i>, 2010, 30(7):661-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20575631/pubmed\" target=\"_blank\" id=\"20575631\">20575631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JO, Polovich M, McNiff KK, et al, &ldquo;American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards,&rdquo; <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19786650/pubmed\" target=\"_blank\" id=\"19786650\">19786650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jagannath S, Barlogie B, Berenson JR, et al, &ldquo;Bortezomib in Recurrent and/or Refractory Multiple Myeloma; Initial Clinical Experience in Patients With Impaired Renal Function,&rdquo; <i>Cancer</i>, 2005, 103(6):1195-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15690325/pubmed\" target=\"_blank\" id=\"15690325\">15690325</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kastritis E, Anagnostopoulos A, Bamias A, et al, &ldquo;Reversibility of Renal Failure in Newly Diagnosed Patients With Multiple Myeloma Treated With High-Dose Dexamethasone Containing Regimens and the Impact of Novel Agents,&rdquo; <i>Blood</i>, 2006, 108(11):3586 [abstract 3586 from 2006 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20085941\"></a>Kastritis E, Wechalekar AD, Dimopoulos MA, et al, &ldquo;Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis,&rdquo; <i>J Clin Oncol</i>, 2010, 28(6):1031-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20085941/pubmed\" target=\"_blank\" id=\"20085941\">20085941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan ML, Reeder CB, Kumar SK, et al, &ldquo;A Comparison of Lenalidomide/Dexamethasone versus Cyclophosphamide/Lenalidomide/Dexamethasone versus Cyclophosphamide/Bortezomib/Dexamethasone in Newly Diagnosed Multiple Myeloma,&rdquo; <i>Br J Haematol</i>, 2012, 156(3):326-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22107129/pubmed\" target=\"_blank\" id=\"22107129\">22107129</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamm W, Willenbacher W, Lang A, et al, &quot;Efficacy of the Combination of Bortezomib and Dexamethasone in Systemic AL Amyloidosis,&quot; <i>Ann Hematol</i>, 2011, 90(2):201-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20821326/pubmed\" target=\"_blank\" id=\"20821326\">20821326</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leal TB, Remick SC, Takimoto CH, et al, &ldquo;Dose-Escalating and Pharmacological Study of Bortezomib in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study,&rdquo; <i>Cancer Chemother Pharamcol</i>, 2011, 68(6):1439-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21479634/pubmed\" target=\"_blank\" id=\"21479634\">21479634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstr&ouml;m's Macroglobulinemia. <i>Blood</i>. 2016;128(10):1321-1328.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/27432877/pubmed\" target=\"_blank\" id=\"27432877\">27432877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al, &ldquo;Pharmacokinetics and Safety of Bortezomib in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432,&rdquo; <i>Clin Cancer Res</i>, 2012, 18(10):2954-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22394984/pubmed\" target=\"_blank\" id=\"22394984\">22394984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mateos MV, Richardson PG, Schlag R, et al, &ldquo;Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-up and Impact of Subsequent Therapy in the Phase III VISTA Trial,&rdquo; <i>J Clin Oncol</i>, 2010, 28(13):2259-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20368561/pubmed\" target=\"_blank\" id=\"20368561\">20368561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mikhael JR, Belch AR, Prince HM, et al, &ldquo;High Response Rate to Bortezomib With or Without Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Results of a Global Phase 3b Expanded Access Program,&rdquo; <i>Br J Haematol</i>, 2009, 144(2):169-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19036114/pubmed\" target=\"_blank\" id=\"19036114\">19036114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moreau P, Coiteux V, Hulin C, et al, &ldquo;Prospective Comparison of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma,&rdquo; <i>Haematologica</i>, 2008, 93(12):1908-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/18768528/pubmed\" target=\"_blank\" id=\"18768528\">18768528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. <i>Clin Pharmacokinet</i>. 2012;51(12):823-829. doi: 10.1007/s40262-012-0010-0.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/23018466/pubmed\" target=\"_blank\" id=\"23018466\">23018466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moreau P, Pylypenko H, Grosicki S, et al, &ldquo;A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients With Relapsed Multiple Myeloma, <i>Blood</i>, 2010, 116(21):312 [abstract 312 from 2010 ASH Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moreau P, Pylypenko H, Grosicki S, et al, &quot;Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Relapsed Multiple Myeloma: A Randomised, Phase 3, Non-Inferiority Study,&quot; <i>Lancet Oncol</i>, 2011, 12(5):431-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21507715/pubmed\" target=\"_blank\" id=\"21507715\">21507715</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor OA, Wright J, Moskowitz C, et al &ldquo;Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2005, 23(4):676-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15613699/pubmed\" target=\"_blank\" id=\"15613699\">15613699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orlowski RZ, Nagler A, Sonneveld P, et al, &quot;Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression,&quot; <i>J Clin Oncol</i>, 2007, 25(25):3892-901.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17679727/pubmed\" target=\"_blank\" id=\"17679727\">17679727</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Bringhen S, Rossi D, et al, &ldquo;Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance With Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients,&rdquo; <i>Blood</i>, 2009, 114(22):128 [abstract 128 from ASH 2009 Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016;375(8):754-766.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/27557302/pubmed\" target=\"_blank\" id=\"27557302\">27557302</a>]</span><span class=\"doi\">10.1056/NEJMoa160</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pekol T, Daniels JS, Labutti J, et al, &ldquo;Human Metabolism of the Proteasome Inhibitor Bortezomib: Identification of Circulating Metabolites,&rdquo; <i>Drug Metab Dispos</i>, 2005, 33(6):771-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15764713/pubmed\" target=\"_blank\" id=\"15764713\">15764713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrone G, Hideshima T, Ikeda H, et al, &ldquo;Ascorbic Acid Inhibits Activity of Bortezomib <i>in vivo</i>,&rdquo; <i>Leukemia</i>, 2009, 23(9):1679-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19369963/pubmed\" target=\"_blank\" id=\"19369963\">19369963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reece DE, Hegenbart U, Sanchorawala V, et al, &quot;Efficacy and Safety of Once-Weekly and Twice-Weekly Bortezomib in Patients With Relapsed Systemic AL Amyloidosis: Results of a Phase 1/2 Study,&quot; <i>Blood</i>, 2011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/21562045/pubmed\" target=\"_blank\" id=\"21562045\">21562045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reeder CB, Reece DE, Kukreti V, et al, &ldquo;Once- versus Twice-Weekly Bortezomib Induction Therapy With CyBorD in Newly Diagnosed Multiple Myeloma,&quot; <i>Blood</i>, 2010, 115(16):3416-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20413666/pubmed\" target=\"_blank\" id=\"20413666\">20413666</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richardson PG, Sonneveld P, Schuster M, et al, &ldquo;Extended Follow-up of a Phase 3 Trial in Relapsed Multiple Myeloma: Final Time-to-Event Results of the APEX Trial,&rdquo; <i>Blood</i>, 2007, 110(10):3557-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17690257/pubmed\" target=\"_blank\" id=\"17690257\">17690257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richardson PG, Sonneveld P, Schuster MW, et al, &ldquo;Reversibility of Symptomatic Peripheral Neuropathy With Bortezomib in the Phase III APEX Trial in Relapsed Multiple Myeloma: Impact of a Dose-Modification Guideline,&rdquo; <i>Br J Haematol</i>, 2009, 144(6):895-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19170677/pubmed\" target=\"_blank\" id=\"19170677\">19170677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richardson PG, Sonneveld P, Schuster MW, et al, &ldquo;Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma,&rdquo; <i>N Engl J Med</i>, 2005, 352(24):2487-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/15958804/pubmed\" target=\"_blank\" id=\"15958804\">15958804</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. <i>N Engl J Med</i>. 2015;372(10):944-953. doi: 10.1056/NEJMoa1412096.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25738670/pubmed\" target=\"_blank\" id=\"25738670\">25738670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncol</i>. 2014;15(11):1195-1206. doi: 10.1016/S1470-2045(14)70440-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/25242045/pubmed\" target=\"_blank\" id=\"25242045\">25242045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    San-Miguel JF, Richardson PG, Sonneveld P, et al, &ldquo;Efficacy and Safety of Bortezomib in Patients With Renal Impairment: Results from the APEX Phase 3 Study,&rdquo; <i>Leukemia</i>, 2008, 22(4):842-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/18200040/pubmed\" target=\"_blank\" id=\"18200040\">18200040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    San Miguel JF, Schlag R, Khuageva N, et al, &ldquo;Bortezomib Plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma,&rdquo; <i>N Engl J Med</i>, 2008, 359(9):906-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/18753647/pubmed\" target=\"_blank\" id=\"18753647\">18753647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al, &ldquo;Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial,&rdquo; <i>J Clin Oncol</i>, 2012, 30(24):2946-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/22802322/pubmed\" target=\"_blank\" id=\"22802322\">22802322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19506160\"></a>Treon SP, Ioakimidis L, Soumerai JD, et al, &ldquo;Primary Therapy of Waldenstr&ouml;m Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180,&rdquo; <i>J Clin Oncol</i>, 2009, 27(23):3830-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/19506160/pubmed\" target=\"_blank\" id=\"19506160\">19506160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uttamsingh V, Lu C, Miwa G, et al, &rdquo;Relative Contributions of the Five Major Hyman Cytochromes P450, 1A2, 2C9, 2C19, and 3A4, to the Hepatic Metabolism of the Proteosome Inhibitor Bortezomib,&rdquo; <i>Drug Metab Dispos</i>, 2005, 33(11):1723-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/16103134/pubmed\" target=\"_blank\" id=\"16103134\">16103134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanderloo JP, Pomplun ML, Vermeulen LC, et al, &ldquo;Stability of Unused Reconstituted Bortezomib in Original Manufacturer Vials,&rdquo; <i>J Oncol Pharm Pract</i>, 2011, 17(4):400-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/20926455/pubmed\" target=\"_blank\" id=\"20926455\">20926455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Velcade (bortezomib) [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17709797\"></a>Zinzani PL, Musuraca G, Tani M, et al, &ldquo;Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2007, 25(27):4293-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bortezomib-drug-information/abstract-text/17709797/pubmed\" target=\"_blank\" id=\"17709797\">17709797</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8509 Version 182.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F142137\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855139\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F142156\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F142140\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2655956\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F142141\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F142142\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20339769\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F142157\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F142118\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F142106\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F142120\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130903\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F142119\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475219\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401586\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F142110\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F142123\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F142108\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F142150\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F142112\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F142126\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F142127\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F6894443\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F142116\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F142107\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F142122\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323023\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F142128\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8509|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bortezomib-patient-drug-information\" class=\"drug drug_patient\">Bortezomib: Patient drug information</a></li></ul></div></div>","javascript":null}